Filtered By:
Specialty: Drugs & Pharmacology
Condition: Hypertension

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 409 results found since Jan 2013.

Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries
ConclusionsAppropriate monitoring could be improved for African‐American beneficiaries and beneficiaries with a history of stroke or Alzheimer's disease and related disorders initiating ACE inhibitors or ARBs. Copyright © 2016 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - March 1, 2016 Category: Drugs & Pharmacology Authors: Matthew L. Maciejewski, Bradley G. Hammill, Laura G. Qualls, Susan N. Hastings, Virginia Wang, Lesley H. Curtis Tags: Original Report Source Type: research

Could intensive anti-hypertensive therapy produce the "J-curve effect" in patients with coronary artery disease and hypertension after revascularization?
CONCLUSIONS: For the patients who had CAD and hypertension, intensive anti-hypertensive therapy could produce the "J-curve effect" after revascularization with the optimal blood pressure (BP) range being 120-130/75-80 mmHg. PMID: 27097958 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 23, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

The impact of SPRINT on the future treatment of hypertension: a mini review.
Authors: Chrysant SG Abstract Blood pressure (BP) control is associated with a significant decrease in the risk of coronary artery disease (CAD), stroke and chronic kidney disease (CKD), and U.S. treatment guidelines in 2003 and 2007 recommended a BP reduction to <140/90 mmHg for uncomplicated hypertension and to <130/80 mmHg for hypertension complicated by CAD, diabetes mellitus (DM) or CKD. In hopes of further decreasing the adverse effects of hypertension, more aggressive lowering of systolic blood pressure (SBP) was tested. However, this aggressive control of SBP did not materialize in additional cardiac ...
Source: Drugs of Today - May 19, 2016 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research

Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis
Conclusions Rivaroxaban is a valuable treatment option for patients with biological prostheses, repaired mitral valves, or a tubular aortic graft in order to prevent thromboembolic complications.
Source: Clinical Drug Investigation - July 10, 2016 Category: Drugs & Pharmacology Source Type: research

Cardiac output changes after osmotic therapy in neurosurgical and neurocritical care patients: A systematic review of the clinical literature
ConclusionsMannitol or HTS administration seems to induce an enhancement of cardiac performance; being more prominent after HTS infusion. This effect combined with mannitol‐induced enhancement of diuresis and HTS‐promoted increase of plasma sodium concentration could partially explain the effects of osmotherapy on cerebral hemodynamics.
Source: British Journal of Clinical Pharmacology - December 1, 2017 Category: Drugs & Pharmacology Authors: Georgia Tsaousi, Elisabetta Stazi, Marco Cinicola, Federico Bilotta Tags: SYSTEMATIC REVIEW AND META ‐ANALYSIS Source Type: research

20-hete in the regulation of vascular and cardiac function
Publication date: Available online 23 July 2018Source: Pharmacology & TherapeuticsAuthor(s): Petra Rocic, Michal Laniado SchwartzmanAbstract20-HETE, the ω-hydroxylation product of arachidonic acid catalyzed by enzymes of the cytochrome P450 (CYP) 4A and 4F gene families, is a bioactive lipid mediator with potent effects on the vasculature including stimulation of smooth muscle cell contractility, migration and proliferation as well as activation of endothelial cell dysfunction and inflammation. Clinical studies have shown elevated levels of plasma and urinary 20-HETE in human diseases and conditions such as hypertension, ...
Source: Pharmacology and Therapeutics - July 24, 2018 Category: Drugs & Pharmacology Source Type: research

Role of GSPE in improving early cerebral vascular damage by inhibition of Profilin-1 expression in a ouabain-induced hypertension model.
CONCLUSIONS: We detected that GSPE could improve cerebral vascular damage through inhibiting Profilin-1 in an ouabain-induced hypertension model. PMID: 30402867 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - November 9, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
AbstractBlood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin –angiotensin–aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10% the incidence of CV mortality, non-fata l myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients. Despite simila...
Source: Advances in Therapy - December 27, 2018 Category: Drugs & Pharmacology Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Uric acid in metabolic and cerebrovascular disorders: a review.
CONCLUSION: UA, which is associated with arterial hypertension and cardiovascular diseases, represents one of the indicators of oxidative homeostasis. Increasing concentrations represent a status of active inflammation which is observed with metabolic and cerebrovascular diseases. PMID: 31845632 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - December 16, 2019 Category: Drugs & Pharmacology Authors: Cortese F, Scicchitano P, Meliota G, Giordano P, Ciccone MM Tags: Curr Vasc Pharmacol Source Type: research

Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants.
Conclusion and Relevance: The HAS-BLED, HEMORR2HAGES, RIETE, and CHEST scores were found to have sufficient diagnostic accuracy for predicting risk of major bleeding in our study population; however, no score was identified as having an AUC greater than 0.7. Caution may be considered when utilizing these scores for patients on DOACs. PMID: 32517484 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 8, 2020 Category: Drugs & Pharmacology Authors: Tchen S, Ryba N, Patel V, Cavanaugh J, Sullivan JB Tags: Ann Pharmacother Source Type: research

U.S. Trends in Prescription Nonsteroidal Anti ‐inflammatory Drug Use Among Patients with Cardiovascular Disease, 1988–2016
ConclusionsPrescription NSAID use among patients with CVD appears to have declined from 1988 to 2016, primarily due to reduced COX ‐2‐selective inhibitor use. Nonetheless, the prevalence of prescription NSAIDs has persisted among a subset of high‐risk CVD populations.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 24, 2020 Category: Drugs & Pharmacology Authors: Andrew Y. Hwang, Steven M. Smith Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy.
CONCLUSION: The incidence of GI bleeding was lower in AF patients who received rivaroxaban compared to those treated with warfarin. Also, GI bleeding risk does not change according to the consumption of other anti-coagulant drugs and un-derlying history of hypertension or stroke in patients received rivaroxaban. Therefore, rivaroxaban is suggested as the choice of prophylaxis in patients with AF and concomitant coagulopathy. PMID: 33390152 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Disorders Drug Targets - January 5, 2021 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

U.S. trends in prescription nonsteroidal anti ‐inflammatory drug use among patients with cardiovascular disease, 1988–2016
ConclusionsPrescription NSAID use among patients with CVD appears to have declined from 1988 to 2016, primarily due to reduced COX ‐2‐selective inhibitor use. Nonetheless, the prevalence of prescription NSAIDs has persisted among a subset of high‐risk CVD populations.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - January 9, 2021 Category: Drugs & Pharmacology Authors: Andrew Y. Hwang, Steven M. Smith Tags: ORIGINAL RESEARCH ARTICLE Source Type: research